Canton Hathaway’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Canton Hathaway's PTGX Position: Q3 2026 in Review
Canton Hathaway held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 1,000 shares worth $141K. The position accounts for 0.03% of the portfolio, ranked #146.
Canton Hathaway first reported a position in PTGX in Q4 2025 and has held it in 4 quarters since. 376 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Canton Hathaway held 1,000 shares of Protagonist Therapeutics worth $141K as of Q3 2026.
- Canton Hathaway left its Protagonist Therapeutics share count unchanged in Q3 2026.
- Protagonist Therapeutics made up 0.03% of Canton Hathaway's portfolio in Q3 2026, its #146 holding.
- Canton Hathaway first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 4 quarters since.
- 376 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Canton Hathaway's 13F filing for Q3 2026, filed 23 Oct 2026.